Skip to main navigation Skip to search Skip to main content

The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis

  • Taha Lodhi
  • , Colm Leonard
  • , Pilar Rivera Ortega
  • , Helen Morris
  • , Tracey Marshall
  • , Katherine Zakis
  • , Theresa Garfoot
  • , Conal Hayton
  • , Melanie Greaves
  • , John Blaikley
  • , Nazia Chaudhuri

Research output: Contribution to journalConference articlepeer-review

Abstract

Background: Idiopathic Pulmonary Fibrosis (IPF) is a debilitating lung disease with mean life expectancy of 3-5 years. With the advent of antifibrotics early detection and diagnosis is paramount to impact disease pathogenesis.

Aim: Investigate if a network based approach to care impacts on earlier detection of IPF.

Methods: We have a network based approach to care in the North West of England with the aim of facilitating early diagnosis and equal access to therapies for IPF. Symptom duration, forced vital capacity (FVC) and transfer factor (DLCO) at diagnosis were compared from 2014 to 2016. ANOVA and Pearson correlation coefficient analysis was conducted.

Results: Overall, there were 330 records across 2014 (n=107), 2015 (n=177) and 2016 (n=130). At diagnosis symptom duration of less than 12 months increased from 8% in 2014 to 32% in 2016. Conversely IPF patients with symptoms greater than 2 years decreased from 71% in 2014 to 52% in 2016. Percentage predicted mean FVC declined from 2.69 (80%) in 2014 to 2.38 (75%) in 2016, meanwhile the mean DLCO increased from 3.59 (41%) in 2014 to 4.0 (45%) in 2016 (p=0.0425). There was a negative correlation with FVC (R2=0.997) and a positive correlation with DLCO percentages (R2=0.902).

Conclusions: Our hypothesis is that a network based approach to IPF care would diagnose patients earlier over time. Here we demonstrate over a 3 year period that more patients had shorter duration of symptoms and higher DLCO at presentation denoting potential earlier diagnosis of IPF. The lower FVC over time is likely driven by the UK regulation restriction for prescribing antifibrotics.
Original languageEnglish
Article numberPA2916
JournalEuropean Respiratory Journal
Volume52
Issue numberSuppl 62
DOIs
Publication statusPublished online - 19 Nov 2018

Bibliographical note

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this